Compare Smith & Nephew plc (SNN) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| SNN | SPLV | |
|---|---|---|
Market Cap | $11.10B | $6.94B |
Volume | 1,051,703 | 1,663,703 |
Sector | Health | — |
52-Week High | $37.17 | $77.97 |
52-Week Low | $26.42 | $70.30 |
Typical Hold Time | 120 Days | 123 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
SPLV trades at $71.22, down 0.71% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $72. Recent news highlights sector overweights in Utilities and Real Estate as headwinds, with the fund lagging the S&P 500's performance. Dividend payments of $0.14 are scheduled for July and September 2026.
Outlook remains cautious due to technical weakness and unappealing growth-adjusted valuation. Risks include concentrated sector exposure and macroeconomic pressures. The fund's low-volatility strategy may appeal during market uncertainty, but current technicals suggest limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
